Zosano secured significant financing of $90 million from four experienced venture teams:

• New Enterprise Associates (NEA)
• Nomura Phase4 Ventures
• HBM BioVentures
• ProQuest Investments

New Enterprise Associates (NEA)
NEA has been helping to build great companies since 1978. Our committed capital has grown to approximately $8.5 billion and we’ve funded more than 550 companies in the IT and healthcare sectors. For more information: http://www.nea.com

Nomura Phase4 Ventures
Phase4 Ventures is a global life science investor whose mission is to provide a premium rate of return for investors by creating, identifying and investing in development stage healthcare companies through its dedicated fund. Phase4 Ventures invests in biopharma, specialty pharmaceutical and medical device companies in the US and Europe.
The team of eight investment professionals has experience in medical, scientific, legal and financial disciplines, with a core expertise in structuring investments appropriate for the stage of the company. The Phase4 Ventures team has worked together for over eight years and possesses a high degree of knowledge, professional expertise and networks in healthcare, finance and investment management. The team is complemented by three venture partners who assist in deal sourcing, diligence and post investment management. Phase4 Ventures also leverages an extensive group of advisors with operating experience at a senior level in pharmaceutical and biotechnology companies.
For more information: http://www.nomura.com/npv

HBM BioVentures
HBM BioVentures invests worldwide in the human medicine / biotechnology and medical technology sectors. As a venture capital company it manages a mature, widely diversified portfolio of private and young small-cap public companies. Investors value HBM BioVentures as an integral part of their healthcare portfolio, giving them access to this newly created investment segment with its high value creation potential.
HBM BioVentures is an active, long-term investor in research and development which finances, accompanies and supports portfolio companies as a key partner. With net assets of over CHF 1 billion, HBM BioVentures is one of the most liquid investments in this sector. Lean structures ensure a competitive cost structure, while wide-ranging expertise, operating industrial experience, highest professional standards and transparency distinguish the company. HBM BioVentures Ltd has a broad shareholder base.
For more information: http://www.hbmbioventures.net.

ProQuest Investments
Founded in 1998, ProQuest Investments is a healthcare venture capital firm with over $875 million under management. We have 12 deal professionals and three offices, our headquarters in Princeton, and additional offices in San Diego and Montreal.
We invest in healthcare companies seeking financings ranging from seed to late-stage. Our portfolio reflects the rich diversity of the healthcare industry and exemplifies our commitment to fostering the growth of exceptional businesses. In addition to our breadth of experience across many sectors of the healthcare industry, we have special expertise in therapeutics, where innovations in drug discovery technologies and molecular analysis are transforming an enormous unmet medical need. With a proven superior track record and over 40 investments in such diverse therapeutic categories as oncology, pain and infectious disease, ProQuest Investments seeks to build long term, mutually beneficial partnerships with outstanding entrepreneurs.
At the end of 2006, ProQuest Investments closed its fourth fund of $425 million.
For more information: http://www.proquestvc.com.